Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 4/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197876 | 0.94 | ALDH1A1 (0.39) | CRBNCTSDARALDH1A1CASP1 | |
| SCHEMBL367375 | 0.86 | — | — | |
| SCHEMBL367376 | 0.86 | — | — | |
| SCHEMBL14749809 | 0.86 | — | — | |
| SCHEMBL8090216 | 0.78 | — | — | |
| SCHEMBL11233543 | 0.78 | CRBN (0.33) | CRBNOR51E2FKBP5 | |
| SCHEMBL5991463 | 0.76 | — | — | |
| SCHEMBL13438779 | 0.76 | — | — | |
| SCHEMBL7624743 | 0.75 | ALDH1A1 (0.40) | CTSDALDH1A1CASP1HSD17B10BACE1 | |
| SCHEMBL9666729 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234984-A1 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | ANIXA BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234984-A1 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | ANIXA BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3228619-B1 | PROCESS FOR THE PREPARATION OF APIXABAN | ZAKL FARMACEUTYCZNE POLPHARMA SA (PL) | 2020-07-29 | — | — | EP | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8362008-B2 | Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors | THE UNIVERSITY OF EDINBURGH (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| EP-1934179-B1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMA (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | ROGER WILLIAMS HOSPITAL (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885CTSD 996/4885AR 3077/4885 |
| US-20230234984-A1 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | SERPINB1, PREP, HPN | CRBN 753/4885CTSD 39/4885AR 4573/4885 |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CRBN 2721/4885CTSD 2843/4885AR 780/4885 |
| US-20080249028-A1 | Thyrotropin-Releasing Hormone Analogs and Method of Use | TRHR, IAPP, TRHDE | CRBN 4026/4885CTSD 1269/4885AR 3019/4885 |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | CRBN 1849/4885CTSD 2350/4885AR 3976/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885CTSD 996/4885AR 3077/4885 |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | CRBN 3895/4885CTSD 4486/4885AR 1270/4885 |
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | CRBN 1849/4885CTSD 2350/4885AR 3976/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | CRBN 3925/4885CTSD 2953/4885AR 566/4885 |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885CTSD 996/4885AR 3077/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | CRBN 2473/4885CTSD 996/4885AR 3077/4885 |
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | CRBN 1849/4885CTSD 2350/4885AR 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.